Atea PharmaceuticalsNASDAQ: AVIR

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Dr. Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Dr. Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Isabella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.

Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.

Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.

New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Arantxa Horga - Chief Medical Officer Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Wednesday, June 5, 2024 at 10:30 a.m. ET in New York.